Partnership Forum: Participants discussed how digital therapeutics with web and designed based applications are emerging as a means to treat conditions by engaging people to improve health and wellness.

December 2023 Legislative & Regulatory Briefing: AMCP Signs Joint Statement Fighting Fake Medicines Bought Online; AMCP Comments on Coverage of Over-the-Counter Preventive Services; AMCP Comments on Advancing Governance, Innovation, and Risk Management for Agency Use of Artificial Intelligence; AMCP Offers Comments on Medication Guides, Patient Medication Information; AMCP Comments on Biosimilar Labeling Guidance.

This sponsored webinar focuses on the burden of Major Depressive Disorder (MDD) and the impact of an atypical antipsychotic approved for the adjunctive treatment of MDD.

This advisory group was active from March 2021-June 2022.

On September 18, 2023, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled “Regulatory Considerations for Prescription Drug Use-Related Software”. This guidance describes how FDA intends to apply its drug-labeling authority to certain software outputs for use with a prescription drug or a prescription drug-led, drug-device combination product. In this guidance, prescription drug use related software generally includes software that (1) is disseminated by or on behalf of a drug sponsor and (2) produces an end-user output that supplements, explains, or is otherwise textually related to one or more of the sponsor’s drug products. FDA considers end-user output a type of prescription drug labeling. AMCP submitted comments in response to this guidance on December 18, 2023.

These AMCP, AMCP Learn, and Journal of Managed Care & Specialty Pharmacy resources will help advance the role of value-based contracts to improve access and affordability of medications.

AMCP's most recent Partnership Forum drew participants from a range of backgrounds and perspectives to discuss the value of collaboration between health plans/payers and patient advocacy organizations in managed care pharmacy decision-making. Senior VP of Professional and Government Affairs Jennifer Mathieu shares key insights and takeaways from the event.

Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. While hair can be lost from any part of the body, alopecia areata usually affects the head and face.

This sponsored webinar explores the unique product characteristics of different botulinum toxin type A (BoNT/A) products and the clinical implications of these differences.

An AMCP event.